April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Inhibition Of Angiogenesis By Fc-endostatin
Author Affiliations & Notes
  • Robert T. Wicks
    Wilmer Eye Institute,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Junko Yoshida
    Wilmer Eye Institute,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Andrea Zambrano
    Wilmer Eye Institute,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Betty Tyler
    Dept. of Neurosurgery,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Kashi Javaherian
    Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts
  • Peter Gehlbach
    Wilmer Eye Institute,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Yassine J. Daoud
    Wilmer Eye Institute,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Henry Brem
    Dept. of Neurosurgery,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Walter J. Stark
    Wilmer Eye Institute,
    Johns Hopkins University SOM, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Robert T. Wicks, None; Junko Yoshida, None; Andrea Zambrano, None; Betty Tyler, None; Kashi Javaherian, None; Peter Gehlbach, None; Yassine J. Daoud, None; Henry Brem, None; Walter J. Stark, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6694. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert T. Wicks, Junko Yoshida, Andrea Zambrano, Betty Tyler, Kashi Javaherian, Peter Gehlbach, Yassine J. Daoud, Henry Brem, Walter J. Stark; Inhibition Of Angiogenesis By Fc-endostatin. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6694. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Endostatin is a potent angiogenic inhibitor with a brief, 2 hour half-life. Fc-endostatin (FcE) is a recombinant form of human endostatin bound to the Fc domain of IgG antibody, which increases its half-life to several weeks. We assessed the antiangiogenic effect of subconjunctival injected FcE compared to bevacizumab (Avastin®) (BV), using a rabbit VEGF-induced corneal neovascularization, micropocket assay.

Methods: : Neovascularization was induced in rabbit corneas through intrastromal implantation of VEGF polymer at 6 and 12 o’clock, 2mm from the limbus. A total of 32 pellets were placed in the 16 eyes of 8 adult rabbits. Rabbits were randomized to 4 treatment groups, each receiving subconjunctival injections in both eyes on Days 0, 5, 8, and 12 of: 1) 0.1mL saline, 2) 0.1mL BV 25mg/mL, 3) 0.125mL FcE 2mg/mL (FcE 2), or 4) 0.125mL of FcE 20mg/mL (FcE 20). Corneas were digitally-imaged on Days 0, 5, 8, 12, and 15. An angiogenesis index (AI) was calculated [vessel length (mm) x vessel number] for each polymer observation.

Results: : All treatment groups showed a significant decrease in the AI compared to saline on all observation days (p<0.001). FcE 2 decreased angiogenesis by a factor of 8.1, 7.0, 8.8, and 6.8 on Days 5, 8, 12, and 15, respectively. FcE 20 decreased angiogenesis by a factor of 68, 2.7, 3.6, and 2.4 at 5, 8, 12, and 15 days. BV, the positive control, decreased VEGF-induced angiogenesis compared to saline by a factor of 138 on Day 15, with no vessel growth at 5, 8, and 12 days. BV was a significantly better inhibitor than FcE 20 by Day 8 (p<0.01). By Day 15, FcE 2 inhibited angiogenesis significantly better than FcE 20 (p<0.01).

Conclusions: : FcE at both 2mg/mL and 20mg/mL doses significantly inhibited angiogenesis. Lower concentration FcE 2 exhibited better inhibition of vessel growth than FcE 20. These results are consistent with previous FcE studies referencing a biphasic dose-response curve. FcE 20 was found to be a less potent VEGF inhibitor than BV. FcE should be further investigated as a novel therapy for corneal neovascularization.

Keywords: neovascularization • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×